LABORATORY AND CLINICAL STUDIES WITH BRL25000 (CLAVULANIC ACID-AMOXICILLIN) IN THE FIELD OF OTORHINOLARYNGOLOGY

• Published in: CHEMOTHERAPY Vol. 30; no. Supplement2; pp. 626 - 632
• Main Authors: HATANO, TSUTOMU, BABA, SHUNKICHI, WADA, KENJI, MURAI, KANETAKA, KINOSHITA, HARUJI, SOYANO, KAORU, SUGIYAMA, KAZUKO, HONDO, JUN, NODA, MASARU, UMEDA, KEIKO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25.11.1982
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.30.Supplement2_626

In laboratory and clinical studies of BRL25000, the following results were obtained. 1) Antibacterial activity of BRL25000 was measured by the plate dilution method on organisms isolated from clinical patients and was compared with that of AMPC. MICs of BRL 25000 against S. aureus, S. epidermidis and Klebsiella were lower than those of AMPC. MICs of BRL 25000 against P. mirabilis and E. coli were similar to those of AMPC due to their sensitivity. 2) Serum levels and the tissue levels of tonsil were determined 1 hour after oral administration of 750 mg BRL25000 in 3 cases. The mean levels were AMPC 1.01μg/ml, CVA 0.47μg/ml in tonsil and AMPC 3.26μg/ml, CVA 3.04μg/ml in serum, respectively. The ratio of AMPC to CVA in tonsil was 2 to 1. 3) BRL25000 was used clinically in 16 cases of ear, nose, throat and larynx infections, and the effective rate was 78.6%(11/14) excluding 2 cases. No side effects were observed.